In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 2, 2007, Pages 583-589

  Roos, Nina ^a   Poulalhon, Nicolas ^a   Farge, Dominique ^a,b   Madelaine, Isabelle ^b   Mauviel, Alain ^a   Verrecchia, Franck ^a,b  

^a INSERM   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; INTERSTITIAL COLLAGENASE; MESSENGER RNA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; CELL ACTIVITY; CELL MOTILITY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; SYSTEMIC SCLEROSIS;

ACTINS; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MATRIX METALLOPROTEINASE 1; MYCOPHENOLIC ACID;

EID: 34247264458     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.117051     Document Type: Article

References (37)

1. Abraham DJ and Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26:587-595.
2. Allison AC and Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47:85-118.
3. Arai S and Vogelsang GB (2000) Management of graft-versus-host disease. Blood Rev 14:190-204.
4. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C, Hartmann DJ, Desmouliere A, and Laville M (2000) Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 58:51-61.
5. Boast S, Su MW, Ramirez F, Sanchez M, and Avvedimento EV (1990) Functional analysis of cis-acting DNA sequences controlling transcription of the human type I collagen genes. J Biol Chem 265:13351-13356.
6. Chen SJ, Artlett CM, Jimenez SA, and Varga J (1998) Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. Gene (Amst) 215:101-110.
7. Ciancio G, Miller J, and Gonwa TA (2005) Review of major clinical trials with mycophenolate mofetil in renal transplantation. Transplantation 80:S191-200.
8. Danovitch GM (2005) Mycophenolate mofetil: a decade of clinical experience. Transplantation 80:S272-S274.
9. Derk CT and Jimenez SA (2003) Systemic sclerosis: current views of its pathogenesis. Autoimmun Rev 2:181-191.
10. Desmouliere A, Chaponnier C, and Gabbiani G (2005) Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 13:7-12.
11. Eckes B, Zigrino P, Kessler D, Holtkotter O, Shephard P, Mauch C, and Krieg T (2000) Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 19:325-332.
12. Gabbiani G (2003) The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 200:500-503.
13. Gregory CR, Pratt RE, Huie P, Shorthouse R, Dzau VJ, Billingham ME, and Morris RE (1993) Effects of treatment with cyclosporine, FK 506, rapamycin, mycophenolic acid, or deoxyspergualin on vascular muscle proliferation in vitro and in vivo. Transplant Proc 25:770-771.
14. Grinnell F (1994) Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol 124:401-404.
15. Hess AD (2006) Modulation of graft-versus-host disease: role of regulatory T lymphocytes. Biol Blood Marrow Transplant 12:13-21.
16. Hinz B, Celetta G, Tomasek JJ, Gabbiani G, and Chaponnier C (2001a) Alphasmooth muscle actin expression upregulates fibroblast contractile activity. Mol Biol Cell 12:2730-2741.
17. Hinz B, Mastrangelo D, Iselin CE, Chaponnier C, and Gabbiani G (2001b) Mechanical tension controls granulation tissue contractile activity and myofibroblast differentiation. Am J Pathol 159:1009-1020.
18. Javelaud D, Laboureau J, Gabison E, Verrecchia F, and Mauviel A (2003) Disruption of basal JNK activity differentially affects key fibroblast functions important for wound healing. J Biol Chem 278:24624-24628.
19. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS, and Lee KB (2004) Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. Eur J Haematol 73:56-61.
20. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, and Mayer J (2005) Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 84:681-685.
21. Leask A and Abraham DJ (2004) TGF-beta signaling and the fibrotic response. FASEB J 18:816-827.
22. Liossis SN, Bounas A, and Andonopoulos AP (2006) Mycophenolate mofetil as firstline treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford) 45:1005-1008.
23. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, Cohen S, Falk P, Fung H, Kirschbaum M, et al. (2005) Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11:307-313.
24. Manzia TM, De Liguori Carino N, Orlando G, Toti L, De Luca L, D'Andria D, Cardillo A, Anselmo A, Casciani CU, and Tisone G (2005) Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc 37:2616-2617.
25. Mele TS and Halloran PF (2000) The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 47:215-245.
26. Poulalhon N, Farge D, Roos N, Tacheau C, Neuzillet C, Michel L, Mauviel A, and Verrecchia F (2006) Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin: a direct role as an antifibrotic agent? J Biol Chem 281:33045-33052.
27. Ruzek MC, Jha S, Ledbetter S, Richards SM, and Garman RD (2004) A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50:1319-1331.
28. Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, and Leichtman AB (2005) Immunosuppression: evolution in practice and trends, 1993-2003. Am J Transplant 5:874-886.
29. Singer AJ and Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738-746.
30. Skalli O, Ropraz P, Trzeciak A, Benzonana G, Gillessen D, and Gabbiani G (1986) A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J Cell Biol 103:2787-2796.
31. Stratton RJ, Wilson H, and Black CM (2001) Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 40:84-88.
32. Uitto J and Kouba D (2000) Cytokine modulation of extracellular matrix gene expression: relevance to fibrotic skin diseases. J Dermatol Sci 24 (Suppl 1):S60-S69.
33. Verrecchia F and Mauviel A (2002a) Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis. Curr Rheumatol Rep 4:143-149.
34. Verrecchia F and Mauviel A (2002b) Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Investig Dermatol 118:211-215.
35. Verrecchia F, Mauviel A, and Farge D (2006) Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 5:563-569.
36. Verrecchia F, Wagner EF, and Mauviel A (2002) Distinct involvement of the Jun-N-terminal kinase and NF-kappaB pathways in the repression of the human COL1A2 gene by TNF-alpha. EMBO (Eur Mol Biol Organ) Rep 3:1069-1074.
37. Zeiser R, Marks R, Bertz H, and Finke J (2004) Immunopathogenesis of acute graft-versus-host disease: implications for novel preventive and therapeutic strategies. Ann Hematol 83:551-565.